August 2025 - Page 8 of 9 - NetworkNewsWire

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://nnw.fm/OoaLP). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:10 am

Bollinger Innovations Inc. (NASDAQ: BINI) Drives Commercial EV Leadership with Bold Rebrand, Market Clarity

Mullen Automotive recently brought all of its EV products and brands together under one strong and unified identity — Bollinger Innovations. The pivot to one commercial EV brand comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets. The company’s new identity is also trading under new Nasdaq stock symbol NASDAQ: BINI. The company’s move under one brand clarifies market positioning, creating cohesion across product lines ready to service the commercial vehicle industry. Bollinger Innovations (NASDAQ: BINI), formerly known as Mullen Automotive, has completed a major corporate transformation, officially rebranding and switching its NASDAQ ticker from MULN to…

WednesdayAug 06, 2025 9:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal…

WednesdayAug 06, 2025 9:00 am

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

NetworkNewsWire Editorial Coverage: As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration's…

WednesdayAug 06, 2025 9:00 am

AI, Robotics Are Reshaping the Future of Hospitality

NetworkNewsWire Editorial Coverage: The hospitality industry is rapidly evolving as artificial intelligence (“AI”) and robotics bring sweeping change. Hotels that implement automation are seeing operational costs drop by 30%–40%, along with enhanced guest satisfaction and stronger revenue strategies. The AI-driven hospitality market is projected to surge to $1.46 billion by 2029 with an impressive 57.8% compound annual growth rate (“CAGR”), while the broader hospitality robotics sector is anticipated to expand from $24.38 billion in 2024 to $107.24 billion by 2034. At the forefront of this transformation is Nightfood Holdings Inc. (NGTF) (Profile), an innovator in hospitality that fuses hotel ownership…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://nnw.fm/iu528). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

TuesdayAug 05, 2025 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Set to Leverage Proprietary Tech, New Trade Deals as Magnetic Materials Gatekeeper

Recent White House announcements with EU and Japan outline tariff guidelines, investment commitments. The confluence of trade policy and industrial investment creates a strategic trade windfall for U.S. critical minerals. Ucore’s proprietary RapidSX technology offers a compelling supply chain solution. Recent trade agreements with the European Union and Japan are unlocking massive investment that could reshape U.S. manufacturing, particularly for critical components such as permanent magnet materials. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) and its RapidSX(TM) separation technology are strategically positioned to become the North American gatekeeper for magnet-grade rare earth oxides under this new industrial paradigm. Under President…

TuesdayAug 05, 2025 9:45 am

AI Maverick Intel Inc. (BINP): The AI Platform That Might Just Replace Your SDR Team

AI Maverick’s next-gen platform can replicate human-like sales conversations—handling prospecting, objections, and scheduling with no SDR required Recent rollout includes adaptive language models, real-time buying signal detection, and multi-step consultative selling automation Company rebrand reflects shift from biotech to AI-led customer acquisition across sectors like healthcare, transportation, and insurance In a world where sales teams are expected to scale faster than ever, often with fewer resources, the rise of intelligent automation platforms is beginning to redefine how companies engage with prospects. For years, sales development representatives (“SDRs”) have filled the gap between marketing and revenue, conducting outreach, asking discovery questions,…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: August 2025